JPMorgan Chase & Co. Lowers Immunovant (NASDAQ:IMVT) Price Target to $37.00

Immunovant (NASDAQ:IMVT – Get Free Report) had its price objective lowered by research analysts at JPMorgan Chase & Co. from $40.00 to $37.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 132.85% […]

Leave a Reply

Your email address will not be published.

Previous post Daiwa America Downgrades Illumina (NASDAQ:ILMN) to Hold
Next post Wynn Resorts (NASDAQ:WYNN) Sets New 12-Month High on Analyst Upgrade